{
  "nctId": "NCT02828020",
  "briefTitle": "Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine",
  "officialTitle": "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine",
  "protocolDocument": {
    "nctId": "NCT02828020",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2017-05-19",
    "uploadDate": "2018-12-13T18:07",
    "size": 4215077,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02828020/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE3"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "DOUBLE",
  "enrollmentInfo": {
    "enrollmentCount": 1672,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2016-07-22",
    "completionDate": "2017-12-14",
    "primaryCompletionDate": "2017-12-13",
    "firstSubmitDate": "2016-07-07",
    "firstPostDate": "2016-07-11"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* At least a 1-year history of migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd edition, beta version\n* Migraine onset before age 50\n* History of migraines typically lasting between 4 and 72 hours if untreated or treated unsuccessfully and migraine episodes are separated by at least 48 hours of headache pain freedom\n* History of 2 to 8 migraine attacks per month with moderate to severe headache pain in each of the previous 3 months.\n\nExclusion Criteria:\n\n* Difficulty distinguishing migraine headache from other headaches\n* Has taken medication for acute treatment of headache (including acetaminophen, nonsteroidal anti-inflammatory drugs \\[NSAIDs\\], triptans, ergotamine, opioids, or combination analgesics) on 10 or more days per month in the previous 3 months\n* Has a history of migraine aura with diplopia or impairment of level of consciousness, hemiplegic migraine, or retinal migraine\n* Has a current diagnosis of new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy\n* Required hospital treatment of a migraine attack 3 or more times in the previous 6 months\n* Has a chronic non-headache pain condition requiring daily pain medication\n* Has a history of malignancy in the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer\n* Has a history of any prior gastrointestinal conditions (eg, diarrhea syndromes, inflammatory bowel disease) that may affect the absorption or metabolism of investigational product; participants with prior gastric bariatric interventions which have been reversed are not excluded\n* Has a history of hepatitis within previous 6 months.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "75 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Percentage of Participants With Pain Freedom at 2 Hours After Initial Dose",
        "description": "Pain freedom was defined as a reduction in headache severity from moderate/severe at baseline to no pain at 2 hours after the initial dose. Participants were provided with an electronic diary (eDiary) to rate headache severity on a scale from no pain to severe pain. Number analyzed is the number of participants with non-missing postdose pain severity assessment at or before 2 hours after initial dose.",
        "timeFrame": "Baseline (Predose) to 2 hours after initial dose"
      },
      {
        "measure": "Percentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial Dose",
        "description": "The most bothersome migraine-associated symptom was the symptom (photophobia, phonophobia or nausea) present at pre-dose baseline identified by the participant to be 'most bothersome'. Participants were provided with an eDiary to record absence or presence of migraine-associated symptoms. Number analyzed is the number of participants with non-missing postdose most bothersome migraine-associated symptoms.",
        "timeFrame": "Baseline (Predose) to 2 hours after initial dose"
      }
    ],
    "secondary": [
      {
        "measure": "Percentage of Participants With Pain Relief at 2 Hours After the Initial Dose",
        "description": "Pain relief was defined as a reduction of a moderate/severe migraine headache to a mild headache or to no headache. Participants were provided with an eDiary to rate headache severity on a scale from no pain to severe pain. Number analyzed is the number of participants with non-missing pain severity assessment at or before 2 hours after initial dose.",
        "timeFrame": "Baseline (Predose) to 2 hours after initial dose"
      },
      {
        "measure": "Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours After Initial Dose",
        "description": "Sustained pain relief was defined as a pain relief at 2 hours with no administration of either rescue medication or the second dose of study drug, and with no occurrence thereafter of a moderate/severe headache up to 24 hours after dosing with study drug. Participants were provided with an eDiary to rate headache severity on a scale from no pain to severe pain. Determinable cases: participants for whom sustained pain relief from 2 to 24 hours status can be determined based on the observed headache severity at scheduled time points, use of rescue medication or optional second dose between 2 and 24 hours, and the answer to the headache recurrence question at 24 hours. Number analyzed is the number of participants with determinable sustained pain relief from 2 to 24 hours after initial dose.",
        "timeFrame": "2 to 24 hours after initial dose"
      },
      {
        "measure": "Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours After Initial Dose",
        "description": "Sustained pain freedom was defined as a pain freedom at 2 hours with no administration of either rescue medication or the second dose of study drug, and with no occurrence thereafter of a mild/moderate/severe headache up to 24 hours after dosing with study drug. Participants were provided with an eDiary to rate headache severity on a scale from no pain to severe pain. Determinable cases: participants for whom sustained pain relief from 2 to 24 hours status can be determined based on the observed headache severity at scheduled time points, use of rescue medication or optional second dose between 2 and 24 hours, and the answer to the headache recurrence question at 24 hours. Number analyzed is the number of participants with determinable sustained pain freedom from 2 to 24 hours after initial dose.",
        "timeFrame": "2 to 24 hours after initial dose"
      },
      {
        "measure": "Percentage of Participants With the Absence of Photophobia at 2 Hours After the Initial Dose",
        "description": "Photophobia was defined as sensitivity to light, a migraine-associated symptom. Participants were provided with an eDiary to record absence or presence photophobia. Number analyzed is the number of participants with non-missing postdose photophobia assessment at or before 2 hours after initial dose.",
        "timeFrame": "2 hours after initial dose"
      },
      {
        "measure": "Percentage of Participants With the Absence of Phonophobia at 2 Hours After the Initial Dose",
        "description": "Phonophobia was defined as sensitivity to sound, a migraine-associated symptom. Participants were provided with an eDiary to record absence or presence of phonophobia. Number analyzed is the number of participants with non-missing postdose phonophobia assessment at or before 2 hours after initial dose.",
        "timeFrame": "2 hours after initial dose"
      },
      {
        "measure": "Percentage of Participants With Absence of Nausea at 2 Hours After the Initial Dose",
        "description": "Nausea was a migraine-associated symptom. Participants were provided with an eDiary to record absence or presence of nausea. Number analyzed is the number of participants with non-missing postdose nausea assessment at or before 2 hours after initial dose.",
        "timeFrame": "2 hours after initial dose"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 2,
      "secondaryCount": 6,
      "otherCount": 0,
      "totalCount": 8
    },
    "studyDesign": {
      "phases": [
        "PHASE3"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 79,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:29:52.537Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}